Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04264676
Other study ID # KY2019-066
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 31, 2020
Est. completion date March 2025

Study information

Verified date November 2020
Source Shanghai Jiao Tong University School of Medicine
Contact Jingyuan Fang, MD, PhD
Phone 86-021-58752345
Email jingyuanfang@sjtu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fusobacterium nucleatum (Fusobacterium nucleatum, Fn) has been identified as an independent risk factor for recurrence of colorectal cancer. In this study, oral metronidazole would be used to reduce the abundance of Fn in patients with high Fn, so as to explore whether oral metronidazole can improve the efficacy of postoperative chemotherapy in patients with colorectal cancer.


Description:

Gut microbiota are linked to chronic inflammation and carcinogenesis. Chemotherapy failure is the major cause of recurrence and poor prognosis in colorectal cancer patients. Previously in the investigators' research, the investigators find the contribution of gut microbiota to chemoresistance in patients with colorectal cancer. The investigators found that Fusobacterium nucleatum (Fn) was abundant in colorectal cancer tissues in patients with recurrence post chemotherapy, and was associated with patient clinicopathological characterisitcs. Furthermore, the investigators' bioinformatic and functional studies demonstrated that Fn promoted colorectal cancer resistance to chemotherapy. Metronidazole has been known to treat with anaerobe infection, including Fusobacterium. So oral metronidazole would be used to reduce the abundance of Fn in patients with high Fn, so as to explore whether oral metronidazole can improve the efficacy of postoperative chemotherapy in patients with colorectal cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 294
Est. completion date March 2025
Est. primary completion date March 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Individuals aged 18-75 years - Individuals firstly confirmed by surgery pathology as colorectal cancer (AJCC cancer staging II - III), who need mFOLFOX6 or CapeOX postoperative chemotherapy - Individuals with Fn - deltaCT value in colon tissue samples detected by qPCR =-12 before receiving chemotherapy - Individuals who could tolerate chemotherapy drugs: ECOG (Eastern Cooperative Oncology Group) score =2 points, WBC(White Blood Cell) =4.0×10^9/L, Hb (Hemoglobin) =80g/L, PLT (Platelet) =80×10^9/L, ALT (Alanine Aminotransferase)< 2ULN (Upper Limmit of Normal), Scr (Creatinine)< 1.5ULN - Individuals who participate this study and sign the informed consent form willingly. Exclusion Criteria: - Individuals with colorectal adenoma or non-colorectal cancer, such as inflammatory bowel disease - Individuals with a history of familial adenomatous polyposis (FAP) - Individuals with severe heart, lung, brain, kidney, gastrointestinal or systemic diseases - Individuals who used antibiotics for more than 5 days in 1 month prior to chemotherapy - Individuals with stage I or IV colorectal cancer, or with stage II colorectal cancer who do not need postoperative chemotherapy - Individuals with contraindications for metronidazole - Individuals who unwilling to participate this study,or unwilling to sign the informed consent form - Individuals with any conditions that the researchers considered inappropriate for inclusion

Study Design


Intervention

Drug:
Metronidazole Oral Tablet
Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
Placebo oral tablet
Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.

Locations

Country Name City State
China Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology & Hepatology, Ministry of Health Shanghai Shanghai
China Fudan University Shanghai Cancer Center Shanghai Shanghai
China Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine Shanghai Shanghai
China Zhongshan Hospital affiliated to Fudan University Shanghai Shanghai

Sponsors (6)

Lead Sponsor Collaborator
Shanghai Jiao Tong University School of Medicine Fudan University, Ruijin Hospital, Shanghai Municipal Commission of Health and Family Planning, Shanghai Shenkang Hospital Development Center, Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease Free Survival, DFS The time from the initial surgical treatment of colorectal cancer to the earliest evidence of recurrence. 5 years
Secondary Overall Survival, OS The time from the initial surgical treatment of colorectal cancer to death from any cause. 5 years
Secondary Recurrence Rate, RR Percentage of patients who has recurrence during or after chemotherapy with Metronidazole or Placebo. 3 years, 5 years
See also
  Status Clinical Trial Phase
Completed NCT01570452 - Matrilysin Expression in Different Stages of Colorectal Tumors N/A
Active, not recruiting NCT04304209 - Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer Phase 2
Active, not recruiting NCT04398446 - Effect of Hemp-CBD on Patients With CIPN Phase 2
Recruiting NCT04486378 - A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer Phase 2
Recruiting NCT06314958 - Stage II/III Colorectal Cancer Recurrence
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting NCT04714814 - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Recruiting NCT05898789 - Virtual Rehabilitation for Cancer Survivors N/A
Completed NCT01356264 - Multimodal Prehabilitation for Colorectal Surgery Phase 2
Recruiting NCT04813627 - Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
Recruiting NCT03448549 - SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Phase 3
Recruiting NCT03904537 - A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer Phase 1/Phase 2
Not yet recruiting NCT05131243 - the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer N/A
Recruiting NCT06076811 - DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
Recruiting NCT06111105 - Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Recruiting NCT06342401 - Early Onset Colorectal Cancer Detection
Completed NCT06271980 - Early-Onset Colorectal Cancer Recurrence